These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 7913433)
1. Predictors for prognosis of chronic myelocytic leukemia. Chen SS; Zhang HF; Xue WT; Li K; Wang P; Lui Y Chin Med J (Engl); 1993 Oct; 106(10):760-2. PubMed ID: 7913433 [TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype. Mesárosová A; Hrivnáková A; Klobusická M; Babusíková O Neoplasma; 1995; 42(1):9-14. PubMed ID: 7617076 [TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic characteristics of the blast crisis in chronic myeloid leukemia. López-Karpovitch X; Cárdenas R; Piedras J Rev Invest Clin; 1997; 49(1):31-6. PubMed ID: 9229753 [TBL] [Abstract][Full Text] [Related]
5. Diminished CD10, CD13, and CD15 expression in a differentiated granulocyte population in CML. Cruse JM; Lewis RE; Sanders CM; Webb RN; Beason KL; Lam J; Koehler J Exp Mol Pathol; 2007 Oct; 83(2):274-6. PubMed ID: 17662271 [TBL] [Abstract][Full Text] [Related]
6. The onset of CML in blastic crisis: molecular features. Gregorini A; Filippetti A; Luchetti F; Walker A; Lillington DM; Papa S; Valentini M J Biol Regul Homeost Agents; 1997; 11(3):111-4. PubMed ID: 9498160 [TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of the blast phase of chronic granulocytic leukemia. Canellos GP Hematol Oncol Clin North Am; 1990 Apr; 4(2):359-67. PubMed ID: 2182596 [TBL] [Abstract][Full Text] [Related]
8. [A "primitive" variant of the blast crisis in chronic myeloleukemia]. Baryshnikov AIu; Turkina AG; Moiseenkova IN; Frolova EA; Sediakhina NP; Diagileva OA; Khoroshko ND; Mokeeva RA Ter Arkh; 1995; 67(7):22-5. PubMed ID: 7482298 [TBL] [Abstract][Full Text] [Related]
9. [Blast crisis accompanied by severe DIC of Ph negative chronic myeloid leukemia showing t(9;16) and positive M-BCR/ABL rearrangement]. Fujiwara H; Takahashi N; Tada J; Higuchi T; Harada H; Mori H; Niikura H; Omine M; Fujita K Rinsho Ketsueki; 1997 Aug; 38(8):663-68. PubMed ID: 9311272 [TBL] [Abstract][Full Text] [Related]
10. CD33, CD4-double positive blastic transformation in a patient with chronic myelogenous leukemia. Hirayama Y; Kohgo Y; Kanisawa Y; Fujii S; Ikeda K; Matsunaga T; Ito Y; Sakamaki S; Niitsu Y Int J Hematol; 1993 Jun; 57(3):265-8. PubMed ID: 8364189 [TBL] [Abstract][Full Text] [Related]
11. Lymphoid blast crisis of chronic myelogenous leukemia occurring more than 11 years after receiving an allogeneic bone marrow transplant for chronic myelogenous leukemia in myeloid blast crisis at onset. Fukuno K; Tsurumi H; Yamada T; Oyama M; Matsuyama T; Terakura S; Kodera Y; Moriwaki H Bone Marrow Transplant; 2003 Feb; 31(3):211-3. PubMed ID: 12621483 [TBL] [Abstract][Full Text] [Related]
12. [Analysis of DNA aneuploidy as a tumor marker]. Takamoto S Gan To Kagaku Ryoho; 1989 Jul; 16(7):2329-37. PubMed ID: 2751314 [TBL] [Abstract][Full Text] [Related]
13. Blast crisis of chronic myelogenous leukemia exhibiting immunophenotypic features of a myeloid/natural killer cell precursor. Murase T; Suzuki R; Tashiro K; Morishima Y; Nakamura S Int J Hematol; 1999 Feb; 69(2):89-91. PubMed ID: 10071456 [TBL] [Abstract][Full Text] [Related]
14. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings. Khalidi HS; Brynes RK; Medeiros LJ; Chang KL; Slovak ML; Snyder DS; Arber DA Mod Pathol; 1998 Dec; 11(12):1211-21. PubMed ID: 9872654 [TBL] [Abstract][Full Text] [Related]
15. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927 [TBL] [Abstract][Full Text] [Related]
16. Determination of secondary chromosomal aberrations of chronic myelocytic leukemia. Wang Y; Hopwood VL; Hu P; Lennon A; Osterberger J; Glassman A Cancer Genet Cytogenet; 2004 Aug; 153(1):53-6. PubMed ID: 15325094 [TBL] [Abstract][Full Text] [Related]
17. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758 [TBL] [Abstract][Full Text] [Related]
18. [Importance of DNA-cytometric parameters in the prediction of blast crisis in the course of chronic myelogenous leukemia]. Kropff M; Wenzler T; Wagner A; Muller CP; Böcking A Verh Dtsch Ges Pathol; 1990; 74():126-9. PubMed ID: 1708569 [TBL] [Abstract][Full Text] [Related]
19. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia]. Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031 [TBL] [Abstract][Full Text] [Related]
20. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]